source
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potentialDetailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.STAT · 1mo ago↗ source
- #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearRoche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if…Endpoints · 1mo ago↗ source
- Lawmakers propose China restrictions; #ASCO26 recap; and moreWelcome back to Endpoints Weekly! We had a small team in Chicago last weekend at this year’s ASCO conference. You’ll find a recap of their coverage below, including more details on Revolution Medic…